Bhaskar Purushottam, MD
Cardiovascular Disease · Rapid City, SDNPI 1982804969
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Penumbra, Inc. accounts for 76.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2020 at $48,896 and has fallen 82.6% since, to $8,532 in 2025. Among cardiovascular disease clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $418.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$115K
- Abbott$14K
- Medtronic$7K
- Abiomed$5K
- W. L. Gore & Associates, Inc.$4K
- Boston Scientific$2K
- plus $4K from 25 others
Across 48 payments — averaging $41,581 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.9M
- Penumbra, Inc.$28K
- Boston Scientific$10K
- Bayer$7K
- AstraZeneca$3K
- Medtronic$263
What the payments were for
- Consulting fees$19,71013%
- Speaking & faculty fees$71,20047%
- Travel & lodging$50,39533%
- Food & beverage$9,9447%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 108 | $115,117 |
| Abbott | 26 | $13,687 |
| Medtronic(2 entities) | 44 | $7,450 |
| Abiomed | 31 | $5,232 |
| W. L. Gore & Associates, Inc. | 5 | $3,540 |
| Boston Scientific | 43 | $1,978 |
| Philips North America LLC | 12 | $1,569 |
| Teleflex LLC | 4 | $779 |
| Bard Peripheral Vascular, Inc. | 23 | $626 |
| Endologix LLC | 2 | $305 |
| Johnson & Johnson | 25 | $200 |
| Stryker | 3 | $123 |
| Novartis | 7 | $92 |
| Angiodynamics, Inc. | 1 | $59 |
| Pfizer | 2 | $54 |
| Chiesi USA, Inc. | 4 | $52 |
| Cordis US CORP. | 1 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $42 |
| Amgen | 3 | $36 |
| Organogenesis Inc. | 1 | $36 |
| Cardiva Medical, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Cardiovascular Systems Inc. | 1 | $29 |
| BD | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Silk Road Medical, Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $12 |
| AstraZeneca | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$72,941
- Indigo$45,903
- Omnilink Elite vascular stent system$13,071
- Impella$4,549
- FlowMet$4,200
- GORE VIABAHN Endoprosthesis with Heparin$3,510
- GORE VIABAHN Endoprosthesis$3,510
- TurboHawk$1,772
- Penumbra Coil 400$1,212
- PHOENIX$1,116
- GENERAL - THERAPIES$1,039
- TURNPIKE CATHETER$700
- Penumbra System$368
- Ovation iX Iliac Stent Graft$305
- IN.PACT Admiral$141
- Perclose ProGlide suture mediated closure system$117
- Labosys$108
- RotarexS 6 F x 135 cm$104
- ESPRIT$100
How this compares
$151,249 in reported general payments places this provider in the 95th percentile of 33 cardiovascular disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 25 | $18,122 |
| Cilostazol | 34 | $501 |
| Atorvastatin Calcium | 50 | $492 |
| ClopidogrelClopidogrel Bisulfate | 30 | $292 |
| Cephalexin | 51 | $259 |
| Warfarin Sodium | 27 | $187 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $200 | $18,12225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 33 cardiovascular disease providers in South Dakota.
Other cardiovascular disease in Rapid City
- K HeilmanRapid City$5K
- Alexander SchabauerRapid City$4K
- Rajesh PradhanRapid City$3K
- Drew PurdyRapid City$2K
- Samuel DurrRapid City$2K
- Amid BitarRapid City$1K
- Stephen WasemillerRapid City$961
- Michael D'ursoRapid City$217
- Lewis FerrierRapid City$84
- Naveen RajpurohitSioux Falls$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.